Leucine Rich Bio, known for its revolutionary products that improve gut microbiome health, has raised an undisclosed sum in a pre-series A funding round. Leucine Rich Bio, India's pioneering microbiome startup, has received backing from famous specialists, including gastroenterologists and oncologists, as well as biotech entrepreneurs. This funding comes on the heels of the company's recent inauguration of a microbiome-focused gut health clinic in the heart of Bengaluru, as well as its expansion into the Philippines.

The startup received INR 2.3 crore in pre-seed capital in 2017. Leucine Rich Bio has also been selling its products in Thailand since 2022. To date, the company has shipped products of around INR 1800000. Leucine Rich Bio CEO Kumar Sankaran commented on the investment, saying, "Receiving this investment is a testament to the groundbreaking work we are doing at Leucine Rich Bio". We truly believe in the microbiome's transformative potential in changing the future of healthcare, particularly cancer treatment and care. We are set to make major progress in our objective to harness the power of the microbiome to combat numerous chronic diseases and cancer with this funding.

This round of financing will primarily fund marketing and the development of new products. This capital infusion will allow the company to grow its product portfolio and enhance its R&D capabilities. Leucine Rich Bio grew 20% year on year in the fiscal year 2022-23 and 30% quarter on quarter in the second quarter of the fiscal year 2023-24. Taking a practical approach to the aphorism.

'All diseases begin in the gut', Leucine Rich Bio offers a new self-administered gut microbiota testing kit called 'BugSpeaks'. They also offer a nutritional supplement called 'Rychbiome Indus', which aids in the replenishment of essential beneficial microorganisms in the gut. The company serves a wide range of customers, including celebrities and others concerned about their health. Some people use BugSpeaks to acquire all about their gut health and overall well-being, while others who have NAFLD, IBD, IBS, type 2 diabetes, and hypertension have used specific BugSpeaks to improve their health. In addition to the popularity of BugSpeaks, the company has seen a 101% spike in demand for 'Rychbiome Indus' from 2021-22 to 2022-23.